Sung-Yup Cho

List of Publications by Year
in descending order

Version: 2024-02-01

24 papers	557 citations	687363 13 h-index	642732 23 g-index
24 all docs	24 docs citations	24 times ranked	758 citing authors

#	Article	IF	Citations
1	Cell Type-specific Activation of Intracellular Transglutaminase 2 by Oxidative Stress or Ultraviolet Irradiation. Journal of Biological Chemistry, 2004, 279, 15032-15039.	3.4	97
2	TGFÎ² mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB Journal, 2008, 22, 2498-2507.	0.5	64
3	Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO Journal, 2003, 22, 5273-5282.	7.8	54
4	Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12492-12497.	7.1	46
5	Transglutaminase 2 inhibits apoptosis induced by calciumoverload through down-regulation of Bax. Experimental and Molecular Medicine, 2010, 42, 639.	7.7	44
6	High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Experimental and Molecular Medicine, 2017, 49, e317-e317.	7.7	37
7	Differential incorporation of biotinylated polyamines by transglutaminase 2. FEBS Letters, 2003, 534, 180-184.	2.8	27
8	Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation. International Journal of Molecular Medicine, 2014, 33, 849-855.	4.0	25
9	Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers. Experimental and Molecular Medicine, 2020, 52, 854-864.	7.7	22
10	Degradation of transglutaminase 2 by calciumâ€mediated ubiquitination responding to high oxidative stress. FEBS Letters, 2009, 583, 648-654.	2.8	21
11	Doxorubicin Induces the Persistent Activation of Intracellular Transglutaminase 2 That Protects from Cell Death. Molecules and Cells, 2012, 33, 235-242.	2.6	21
12	CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene, 2021, 40, 3287-3302.	5.9	18
13	A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. Molecular Cancer Therapeutics, 2017, 16, 2178-2190.	4.1	17
14	Genomeâ€scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinibâ€resistant lung cancer. Molecular Oncology, 2021, 15, 487-502.	4.6	15
15	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Letters, 2020, 495, 135-144.	7.2	8
16	Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. Cancer Letters, 2021, 497, 123-136.	7.2	8
17	Alterations in the Rho pathway contribute to Epstein-Barr virusâ€“induced lymphomagenesis in immunosuppressed environments. Blood, 2018, 131, 1931-1941.	1.4	7
18	Transglutaminase 2 mediates transcriptional regulation through BAF250a polyamination. Genes and Genomics, 2021, 43, 333-342.	1.4	6

#	Article	IF	Citations
19	Transglutaminase 2 mediates hypoxia-induced selective mRNA translation via polyamination of 4EBPs. Life Science Alliance, 2020, 3, e201900565.	2.8	6
20	Intimal Hyperplasia in Loop-Injured Carotid Arteries Is Attenuated in Transglutaminase 2-Null Mice. Journal of Korean Medical Science, 2014, 29, 363.	2.5	5
21	Transglutaminase 2 crosslinks the glutathione S-transferase tag, impeding proteinâ€“protein interactions of the fused protein. Experimental and Molecular Medicine, 2021, 53, 115-124.	7.7	5
22	Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. Journal of Breast Cancer, 2022, 25, 178.	1.9	3
23	Significant allelic dropout phenomenon of Oncomine BRCA Research Assay on Ion Torrent S5. Clinical Chemistry and Laboratory Medicine, 2019, 57, e124-e127.	2.3	1
24	Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC. Cancer Research, 2022, 82, 5477-5477.	0.9	0